Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its...
Vaccine
At 2025 STAT Summit, Guests including Joe Kennedy III, AMA President, Former NIH Leaders, Explore CRISPR, Pharma, Public Health, and More
BOSTON, Oct. 17, 2025 /PRNewswire/ -- The seventh annual STAT Summit kicked off Wednesday in Boston, bringing together a carefully curated...
Beautinelle Launches BeneLift Pro: A Groundbreaking FDA-Approved Nano Infusion Device
Elevate your services and maximize profits with the BeneLift® Pro - the next evolution in professional skincare technology. BOCA RATON,...
Meet Caravel: Pioneering a New Era of Biotechnology with the First Unified Platform for Protein Discovery and Delivery
Backed by a $7.8M award from the National Science Foundation, Caravel unlocksbreakthroughs across animal health, biochemical manufacturing, and beyond. PORTLAND,...
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
CAMBRIDGE, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a...
TriNetX Becomes the Most Cited Real-World Data Source in Peer-Reviewed Research
With more than 2,000 citations and year-over-year growth nearing 80%, TriNetX outpaces competitors and fuels high-impact science published in top...
Digital Health Market Size to Worth USD 2688 Billion by 2035 at 22.55% CAGR | Vantage Market Research
NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The Global Digital Health Market is projected to grow from USD 288.55 billion in...
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is...
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed...
Aanastra Inc Announces Presentations of Preclinical Data at Upcoming Conferences in Support of its Lead Programs for Anti-CD19 In Vivo CAR-T (AAN-14x) and In vivo Rescue of P53 Mutations in Tumors (AAN-53x)
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14xMultiple redosing of AAN-14x at...
10x Faster Virus Neutralization Testing With Launch of Integral Molecular’s Ready Reporter Virus™ Kit
Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development PHILADELPHIA, Oct. 14, 2025 /PRNewswire/ -- Integral...
Nanomedicine Market Size to Reach US$ 389.52 Billion by 2033, Driven by Advancements in Targeted Therapies and Drug Delivery Innovations | According DataM Intelligence
AUSTIN, Texas and TOKYO, Oct. 13, 2025 /PRNewswire/ -- The global nanomedicine market size reached US$ 169.51 Billion in 2024...
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,...
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS...
Bavarian Nordic shareholders are reminded of expiry of the offer period regarding the takeover offer from consortium consisting of Nordic Capital and Permira
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire /...
WORK Medical Technology Group LTD Granted Additional 180-Day Period to Regain Nasdaq Compliance
Hangzhou, China, Oct. 10, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”),...
IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa
Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV CAIRO, EGYPT; BERLIN, GERMANY;...
BioNJ’s 13th Annual C-Suite Summit: A Premier Lineup & Bold Agenda
TRENTON, N.J., Oct. 9, 2025 /PRNewswire/ -- BioNJ will host its Thirteenth Annual C-Suite Summit on Thursday, October 30, 2025,...
Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections
FORT LAUDERDALE, FL / ACCESS Newswire / October 9, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company...